AI in Drug Discovery: Founder and Scientist Conversations

AI is used to analyze biological and chemical data, prioritize targets, predict structures and properties, search virtual compound libraries, generate or optimize molecules, estimate ADMET characteristics, and coordinate computational workflows. The exact role depends on the scientific problem and available evidence.

Not in the complete sense implied by the phrase. AI can support or automate parts of discovery, but drug development still requires problem definition, chemistry, biology, experimental validation, manufacturing, regulation, clinical trials, and commercial decisions.

Generative models propose new molecular or biological designs based on learned patterns and defined objectives. Those candidates still need evaluation for potency, selectivity, synthesizability, safety, and experimental performance.

AI agents are software systems that can plan and execute multi-step tasks across tools. An agent might prepare inputs, run calculations, evaluate outputs, and coordinate repeated computational steps. The quality of the underlying tools and scientific validation remains decisive.

Common limitations include incomplete or biased data, weak problem definitions, limited interpretability, poor transfer to new biological contexts, computational constraints, uncertain experimental validity, and the difficulty of translating an early discovery result into a safe and effective medicine.

No. It can prioritize experiments and reduce the number of candidates a team needs to test, but physical experiments remain necessary to validate biological activity, chemistry, safety, and reproducibility.